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1. Introduction  
Renal cell carcinoma (RCC) is the most common cancer of the kidney (Motzer et.al., 1999). In 
the United States each year 57.000 new patients are being diagnosed with RCC resulting in 
12.900 deaths (Linehan et.al., 2011). The median age at diagnosis today is 64 years and even 
though it represents only 3% of all cancers, the incidence is increasing steadily. With rising 
prevalence of some known risk factors like hypertension and population ageing, the incidence 
of RCC is expected to be rising even more in subsequent years. With increasing incidence of 
renal cell carcinoma (RCC) combined with population ageing, questions about the treatment of 
elderly and frail patients with RCC are becoming more and more relevant. Many of the 
patients with newly diagnosed RCC are in advanced age and/or have some major co-
morbidities which often results in their poor performance status. Elderly or frail patients are 
frequently excluded from clinical trials, because the results of their treatment are often difficult 
to interpret. This is also true for patients with heart, lung, liver or other major co-morbidities. 
Excluding these patients from clinical trials leads to lack of evidence-based guidelines for their 
treatment and often poses to oncologists a difficult dilemma when they need to decide what 
treatment options to offer to patients (Scuch et.al., 2008). In the present chapter we would like 
to present current recommendations for diagnostics and treatment of elderly and frail patients 
with RCC. In the second part of the chapter results of the analysis of metastatic RCC patients 
treated in a single institution with emphasis on differences in the treatment between good and 
poor performance status patients are presented. 
2. Age, performance status, co-morbidities and prognostic models 
2.1 Age 
Ageing is a complex process that affects every aspect of life. The US department of Health 
and Human Services Administration of Ageing estimates that 1 in every 8 Americans is 
older than 65 years. In 2006 this group represented 12,4% of the population, but by 2030 this 
number is expected to increase to 20%. With population ageing, incidence of all cancers is 
supposed to be rising in the next years and RCC is no exception (Neustadt et.al., 2008).  
It is well known that the actual age is determined by physiology rather than chronology. 
Factors of biological aging include changes in the physical structure of the body as well as 
changes in the performance of motor skills and sensory awareness. These changes can lead 
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to multiple adverse events during the hospitalisation of an elderly patient especially in the 
postoperative period. Delirium episodes (acute decline of attention and cognition) can occur 
in 15-35% of patients during hospitalisation in the postoperative period and as high as 70-
78% of patients in intensive care units. Prolonged hospitalisation is also associated with falls 
at rate 4-10/1000 patient-days. Other common adverse events are functional decline in 32% 
and adverse events of drugs in 10-15% of patients (Pushkar & Govorov, 2008). 
Organs have a certain capacity to resist to stress and return to normal functioning after the 
stress on them has passed. This concept is termed “organ reserve”. This reserve diminishes with 
age and may explain some functional deterioration in the elderly. Organ reserve in the young is 
supposed to be 7-11 times greater than in the advanced age person. Declining of organ reserve 
with age can not be predicted properly because it is subject to individual variation. Still, it has to 
be taken into account in treatment decision making (Neustadt et.al., 2008). 
The patient’s age is incorporated in the development of treatment decision and often is an 
inclusion /exclusion criterion of clinical trials. For a long time it was believed that older 
patients may tolerate treatment less well and may develop more adverse events compared 
to younger patients. Consequently, many treatments were not offered to older patients only 
on the basis of their chronological age without any strong evidence gained from clinical 
trials. It is becoming more and more clear that older patients may tolerate available 
treatments as well as younger ones and that treatments are being equally effective in both 
groups. Still, not all available treatments can be given without causing harm to all patients 
and some prudence is needed. Evaluation of functional organ reserve, evaluation of co-
morbidities and performance status is of utmost importance (Calvo et.al., 2010).  
2.2 Performance status 
Beside accurate diagnostics and staging of tumours, before the decision on treatment 
modalities, performance status needs to be assessed in all cancer patients. Importance of 
pre-treatment performance status evaluation has been determined on the basis of several 
clinical trials that confirmed its prognostic value. Performance status can be assessed based 
on several different scales. In oncology the most commonly used are Karnofsky scale and 
the ECOG score (published by Oken et al. in 1982), also named WHO or Zubrod score. 
Scores and their comparisons are shown in Tables1 and 2. 
¶ 
Percentage Description
100% Normal, no complaints, no signs of disease 
90% Capable of normal activity, few symptoms or signs of disease 
80% Normal activity with some difficulty, some symptoms or signs 
70% Caring for self, not capable of normal activity or work 
60% Requiring some help, can take care of most personal requirements 
50% Requiring help often, requires frequent medical care 
40% Disabled, requires special care and help 
30% Severely disabled, hospital admission indicated but no risk of death 
20% Very ill, urgently requiring admission, requires supportive measures or 
treatment 
10% Moribund, rapidly progressive fatal disease processes 
Table 1. Karnofsky performance status scale 
www.intechopen.com
 
Treatment of Renal Cell Carcinoma in Elderly and Frail Patients 
 
419 
WHO/ECOG   Description
0 Fully active, able to carry on all predisease activities without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature. For example, light 
housework, office work 
2 Ambulatory and capable of all self care but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair 50% or more of 
waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair 
Table 2. WHO performance status scale 
Karnofsky score of 90-100% corresponds to 0 on WHO scale, 70-80% to 1, 50-60% to 2, 30-
40% to 3 and 10-20% to WHO grade 4. Patient death corresponds to 0% or 5 on Karnofsky 
and WHO scale respectively (Pushkar & Govorov, 2008).  
Poor performance status in patients with RCC can be the result of one or multiple causes 
leading to a heterogeneous group of patients. Causes of poor PS (> 1 WHO) may be directly 
connected to RCC and metastases or may be the result of co-morbidities not directly connected 
to cancer (e.g. cardiovascular or hepatic diseases). Causes of poor PS related to tumour may be: 
pain from primary tumour or metastases, pleural effusion or ascites, brain metastases, 
anaemia, cachexia, gastrointestinal symptoms or fatigue (Pushkar&Govorov, 2008).  
In measuring PS of the patient on WHO or Karnofsky scale some caution is needed because 
there are some situations where assessment of patient’s functional status may require more 
than PS values written in numbers. For example, bone metastases: involvement of pelvis, 
femur or spine can force the patient to become bedridden, and the evaluation of PS in those 
patients can be difficult. Other criticism to the PS scales is that they do not include patient’s 
nutritional status and they don’t assess cachexia. Although performance status assessed 
with WHO or Karnofsky scales may not always reflect the actual functional status of the 
patient it is a most useful tool and should be utilized before and during the treatment of all 
cancer patients (Shuch et.al., 2007). 
2.3 Co-morbidities 
Outcome of therapy is depended not only on type and tumour aggressiveness but also on 
functional status of the patient and co-morbidities. In predicting possible outcome in elderly 
patients, evaluating performance status may not be enough and a thorough evaluation of 
their co-morbidities and organ functional reserve is mandatory. It is estimated that five 
years after the diagnosis of RCC, 30% of patients die because of conditions other than RCC. 
There are several ways to evaluate co-morbidities like American society of anaesthesiology 
(ASA) score used before surgery. Even though none of them is universally accepted, they 
may help us to determine the functional status of the patient (Pushkar & Govorov, 2008).  
Evaluation of co-morbidities is and important part in the treatment decision process; but not 
only that, some of them may even predict the higher risk of developing RCC. The number of 
patients with end stage renal disease has increased markedly and haemodialysis is the most 
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widely used form of renal replacement therapy in the elderly. It has been demonstrated that 
patients on haemodialysis have a higher probability of developing RCC (Ishikawa et.al., 
1990). The overall relative risk of RCC is 5-10-times higher in patients with end-stage renal 
failure (Levine et.al., 1992). To detect RCC early in the course of the disease, these patients 
should have regular urologic follow-ups. The incidence of RCC is also high in patients after 
kidney transplantation. Murphy reported that post-transplant patients have a 1,85 times 
higher risk of development of RCC that their matched controls in the general population. 
This higher risk was not affected by age, gender, ethnical group and time since 
transplantation (Pushkar & Govorov, 2008).  
Neuzillet et.al. evaluated clinicopathologic characteristics and treatment outcome in 1250 
RCC patients with end stage renal disease in comparison with RCC patients without end 
stage renal disease (ESRD). They found that ESRD patients with RCC were younger (55 
vs. 62 years, p<0,01), were more frequently discovered incidentally (87% vs 44%, p<0,01), 
had less local and systemic symptoms and were males (76,5% vs 61,9%, p<0,01) at rate 
compared to RCC patients without ESRD. Tumours were detected at lower stage in 
patients with ESRD, had lower grade and were papillary higher in higher percentage 
(37% vs 7%, p<0,01) in ESRD. Interestingly, more patients with ESRD were in good 
performance status (ECOG 0) (76% vs 63%). Authors conclude that better tumour and 
patient’s characteristics are the results of more abdominal imaging performed in these 
patients. Consequently, more incidental tumours are being diagnosed (Neuzillet et.al., 
2011).  
2.4 Prognostic models 
In the treatment decision making process it is very important to predict the patient’s 
survival. Patients with short predicted survival time should be evaluated carefully and best 
quality of life should be the primary goal of their treatment (Bukowski & Negrier, 2004). 
Motzer et.al. conducted a retrospective trial to identify prognostic factors and to find 
predictive model of survival of patients with metastatic RCC. Pretreatment factors were 
evaluated. They identified five prognostic factors on the basis of which patients can be 
divided into three risk groups (low, intermediate or high) for which the median survival 
time was separated by six months. Patients with zero risk factors (low risk group) had 
median survival of 20 months, those with one or two risk factors (intermediate risk group), 
had median survival time of 10 and those with three or more risk factors (high risk group) 
had survival time of 4 months. The identified prognostic factors (called also Memorial Sloan 
Kettering prognostic factors) were  (Motzer et.al., 1996): 
 Lactate dehydrogenase levels > 1,5 times upper limit of normal 
 Haemogloben level < lower limit of normal 
 Corrected serum calcium level > 10 mg/dl (2,5mmol/l) 
 Interval of less than a year from original diagnosis to the start of systemic treatment   
 Karnofsky performance status < 80 
 Absence of prior nephrectomy 
In another trial conducted in the year 2004, Motzer evaluated survival in previously treated 
patients with metastatic RCC. 251 patients were included in the trial. Identified prognostic 
factors were: 
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 low (<80) Karnofsky performance status 
 low haemoglobin levels 
 high corrected serum calcium.  
Based on these three factors he divided patients into three groups regarding their prognosis. 
The median survival in patients without any of the factors present was 22 months, with one 
factor 11,9 months and those with two or three 5,4 months. Even though his intent was to 
categorize patients into risk groups to better interpret the results of clinical trials, we can use 
this categorisation in assessing predicted survival in our every day clinical practice (Motzer  
et.al., 2004). 
To evaluate Memorial Sloan Kettering prognostic factors, researchers at the Cleveland Clinic 
Taussig Center retrospectively evaluated 353 patients with metastatic RCC that were 
included in clinical trials between 1987 and 2002. Four of the five prognostic factors 
identified by Motzer were independent predictors of survival. In addition, prior 
radiotherapy and presence of hepatic, lung, and retroperitoneal nodal metastases were 
found to be independent prognostic factors. Using these expanded criteria, favorable risk is 
defined as zero or one poor prognostic factor, intermediate risk is two poor prognostic 
factors, and poor risk is more than two poor prognostic factors. Median overall survival 
times of these groups were 26.0, 14,4, and 7,3 months, respectively (P < ,0001) (Bukowski & 
Negrier, 2004, Mekhail et.al, 2005). 
Different models predicting survival other than those developed by Motzer and Cleveland 
group have been proposed. Bamias studied prognostic factors in patients treated with 
sunitinib. He identified three prognostic factors: time from diagnosis to the start of sunitinib 
therapy, number of metastatic sites and performance status (Bamias et.al., 2010). Hudes 
et.al. in a trial with temsirolimus used slightly modified Motser’s factors in selecting poor 
prognosis patients. Instead of absence of prior nephrectomy, metastases in multiple organs 
were included and Karnofsky performance status <70 was used (Hudes et.al., 2007).  
2.5 Definitions of elderly and frail patients 
Elderly population is not an uniform entity, since chronological and biological age can differ 
considerably (Neustadt et.al., 2008). On a basis of the observation that active oncological 
treatment can be outweighed by increased treatment toxicity in this patient population, age 
of 75 years was determined as a milestone for defining elderly patients population (Lane 
et.al., 2010). Frail patients are considered those in poor performance status (WHO>1) 
(Pushkar & Govorov, 2008). According to MSK model, patients with Karnofsky PS<80%had 
worse survival compared to patients with higher score (Motzer, et.al. 1996) 
3. Tumour evaluation 
3.1 Diagnostic procedures 
In tumour evaluation, the diagnostic tests do not differ much between older and younger 
patient populations. In both groups CT is necessary for accurate detection of tumour and 
nodal extension. In patients with renal insufficiency, CT without contrast media or magnetic 
resonance imaging instead of CT is being performed in order to prevent further damage to 
kidneys by using a nephrotoxic contrast media. Abdominal ultrasound is another very 
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useful diagnostic tool that can easily be performed in all patients regardless of their age or 
performance status. The role of percutaneous tumour biopsy is limited in all patients. It may 
be of value in frail patients or in patients with overt metastatic disease to make a diagnosis 
of RCC and to avoid radical nephrectomy (Pushkar & Govorov, 2008). 
3.2 Differences in tumour characteristics between young and elderly patients 
Renal carcinoma is the most common renal parenchymal malignancy. Most of the patients 
are elderly with only 3-7% of RCC occurring in patients younger than 40 years. Trials 
performed in patients with breast, colon and prostate carcinomas showed that younger 
patients have a biologically more aggressive disease that leads to worse prognosis compared 
to elderly patients (Denzinger et.al., 2009).  
To explore this issue in RCC, Denzinger retrospectively evaluated 1042 patients that were 
treated between 1992 and 2005. He compared patients younger than 45 years to patients 
aged over 75. In a multivariate analysis lower age was associated with higher 5-years cancer 
specific survival (95,2% vs 72,3% p=0,009) and lower 5-y progression rate (11,3% vs 42,5% 
p=0,002) (Denzinger et.al., 2009). Komai et.al. also found younger age to be a favourable 
prognostic factor. The 5-year cancer-specific survival rate was significantly better for the 
younger patients than for the older patients (p = ,049). Multivariate analysis showed that age 
was significantly associated with cancer specific survival (Komai et. al. 2011). Similar results 
were obtained in a trial of Jung and co-workers on low stage RCC patients (Jung et.al., 2009). 
These and other trials show uniformly, that younger RCC patients have better prognosis 
compared to the elderly (Denzinger et.al., 2009).  
Trials also uniformly showed that younger patients are more likely to have a lower disease 
stage, lower nuclear grade, and smaller tumor size than older patients (Denzinger et.al., 
2009, Komai et.al., 2011, Jung et.al., 2009).  
4. Surgical treatment of elderly and frail patients 
4.1 Radical and nephron sparing surgery in localized disease 
Surgical resection is effective therapy for clinically localized RCC; with options including 
radical nephrectomy and nephron-sparing surgery. Radical nephrectomy (RN) was for 
many years considered the “gold standard” in the treatment of locally advanced RCC and 
nephron sparing surgery (NSS) was suggested when radical nephrectomy would render the 
patient functionally anephric. These cases included RCC in a solitary kidney, RCC in one 
kidney and the other non functioning and bilateral RCC (NCCN, 2011). 
In recent years nephron-sparing surgery has become more and more popular (NCCN, 2011). 
Several trials showed that in patients with small tumours (<7 cm) the same oncological 
results can be achieved with NSS compared to RN  (NCCN, 2011, Leibovich et.al, 2006, 
Becker et.al., 2006). In the trial of Leibowich the results of 91 patients treated with NSS and 
841 patients treated with RN for 4 to 7 cm RCC between 1970 and 2000 have been compared. 
Cancer specific survival rates at 5 years for patients treated with NSS and RN for 4 to 7 cm 
RCC were 98% and 86%, respectively, the  difference was not statistically significant (risk 
ratio 1,60, 95% CI 0,50-5,12, p = 0,430). Differences were not statistically significant even 
when authors compared the occurrence of local relapse or distant metastases (Leibovich 
et.al, 2006). 
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Nephrectomy (radical or nephron-sparing) should be considered as part of treatment 
decision process in all patients with stage I-III disease fit for surgical procedure (NCCN, 
2011). In elderly or poor performance status patients still amenable for surgery nephron-
sparing nephrectomy rather than radical nephrectomy should be performed whenever 
possible (Lane et.al., 2009). In patients with decreased life expectancy and/or extensive co-
morbidities, surgery represents excessive risk and other options like tumour termoablation 
or active surveillance should be considered (NCCN, 2011) 
4.2 Cytoreductive nephrectomy in patients with metastatic disease 
Multimodality treatment in patients with metastatic RCC consists of surgery combined with 
systemic therapy. Surgical approach consists of cytoreductive nephrectomy often combined 
with metastasectomy of distant metastases. This approach in cancer therapy is distinctly 
different from treatment of other types of cancer. The rationale for nephrectomy is multiple: 
enhancing the effects of systemic therapy, removing the source of distant metastases and 
providing additional tissue for evluation in targeted therapy (Kutikov et.al., 2010).  
To assess the benefit of cytoreductive surgery in patients with poor performance status (PS 
WHO 2 or 3), Shuch et.al. performed a retrospective analysis of all patients who underwent 
CN surgery at the University of California in between 1989 and 2006. They compared the 
results of patients in good (WHO 0,1) with those in poor performance status (WHO 2,3). 
Patients with poor PS had shorter disease-specific survival compared to patients with better 
PS (6 months vs. 27 months). Systemic treatment in CN was administered to only 57,5% of 
patients in poor performance status and no objective response was seen in these patients. 
CN in these patients may be used only to palliate haematuria or pain, but survival benefit of 
CN in poor PS patients is limited. (Scuch et.al., 2008, Kutikov et.al., 2010, Pushkar & 
Govorov, 2008, Chouieri, 2010).  
Cytoreductive surgery should be offered to patients in good performance status only. Beside 
these, patients with lung metastases only and those with good prognostic features benefit 
most from it. The role of CN in the era of targeted therapy has not been defined jet. 
Randomized trials are ongoing and should answer this dilemma (NCCN, 2011).  
4.3 Observation and palliative surgical aproaches 
Observation (so called watchful waiting or active surveillance) is a less aggressive treatment 
modality and should be considered as an option in elderly patients with or without major 
co-morbidities, especially those with small incidentally found tumours and in those with 
larger tumours, but very short life expectancy. For the latter, surgery represents a greater 
risk compared to observation alone. Kassouf et.al. demonstrated that observation is a safe 
option, most of the tumours observed did not show signs of growth and none of the 24 
patients in the trial developed metastases during the 31.6 months of median follow-up 
(Pushkar & Govorov, 2008). 
One question still open is whether to perform tumour biopsy to prove malignity before 
active therapy is delivered. In the past this approach was not frequently adopted, mainly 
because a lot of false negative results found and because of the fear of side effects connected 
to biopsy of renal mass. In recent years renal biopsy became relevant. This is due to the fact 
that 20% of small renal tumours are benign or have low malignant potential. Biopsy should 
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be considered whenever some doubt exists in decision to perform surgery, minimally 
invasive procedures or to observe the patient (Lazzeri et.al., 2010).  
Paliative nephrectomy should be considered in patients with gross haematuria or other 
symptoms related to primary tumour that can not be controlled by non invasive measures, 
like uncontrollable pain (NCCN, 2011). Moreover, it may palliate pain and treat 
paraneoplastic syndromes associated with metastatic RCC (Kutikov et.al., 2010).  
Tumour transarterial embolisation (TAE) in RCC patients has an established role in 
palliative treatment. It can be used to diminish patient’s suffering from pain, haematuria or 
paraneoplastic symptoms. It can be offered as a sole treatment option or preoperatively to 
diminish the blood loss during nephrectomy. Although it is considered a palliative measure, 
80% of patients to whom TAE has been performed, remain disease free after the procedure 
(Lane et.al., 2010). TAE should be offered to patients with short life expectancy, since 
neovascularisation is expected to occur some time after the procedure (de Reijke et.al., 2010).  
Munro et.al evaluated 25 patients treated with TAE. In this survey TAE was performed in 
two groups of patients. The first group consisted of patients with stage IV disease (median 
age 73 years) and the second of mainly elderly (median age 80 years) patients stage I-III 
disease who were unable or unwilling to receive nephrectomy. Authors analysed the 
usefulness of TEA regarding symptom control, hospital stay and survival. The conclusion 
was that embolisation is a good treatment option for palliating symptoms derived from 
primary tumour in patients with advanced disease and those with localized disease and 
poor general condition (Pushkar & Govorov, 2008). Other palliative measures available 
today are cryoablation, radiofrequency ablation, high-intensity focused US; microwave 
thermotherapy and radiosurgery. Results with all these techniques, even if studied in trials 
with small included number of patients, are promising not only in terms of palliation, but 
also in terms of disease free and cancer related survival  (Lazzeri et.al., 2010). 
5. Systemic therapy of metastatic disease 
Despite advances in RCC detection, still 20-30% of patients present with metastatic disease. 
Treatment of metastatic disease in elderly and frail patients represents a big challenge for 
medical oncologists. Until recently there was a widely accepted belief that the treatment 
may not be effective in older patients and that they may be at higher risk of developing 
adverse events than younger patients. Consequently, they were often excluded or 
inadequately represented in clinical trials. However, recent evidence indicates that available 
treatments may be tolerated and effective in all patients regardless of age. Metastatic RCC is 
a chemotherapy resistant disease and until recently treatment options of these patients were 
limited. With the development of targeted therapies, new treatment options became 
available. Yet the question of efficiency and tolerability of this agents in elderly and frail 
patients arose (NCCN, 2011, Scuch et.al., 2008).   
5.1 Treatment with immunotherapy 
Immunotherapy with interferon alfa and interlekin-2 was for a long period the 
cornerstone of systemic treatment of metastatic RCC. Nowadays immunotherapy is being 
successfully replaced by less toxic and more effective targeted therapies. Trials performed 
with immunotherapy have shown that patients with worse performance not only had 
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shorter survival, but also had a decreased response rate to immunotherapy and greater 
frequency 3 and 4 toxicity. Decreased response to immunotherapy is supposed to be due 
to the fact that patients with PS>1 have a compromised immune system; immunotherapy 
success is clearly related to a good immune system. Nevertheless, it is difficult to 
determine whether the treatment is less effective because the performance status is low or 
whether the performance status is low because tumour is more aggressive (Pushkar & 
Govorov, 2008). This, together with tumour characteristics, is the reason why 
immunotherapy was not approved in the treatment of patients with poor performance 
status (Scuch et.al., 2008).  
5.2 Treatment with targeted therapies 
In recent years a whole new spectrum of treatments with targeted drugs became available in 
the treatment of metastatic RCC. These new drugs were tested to treat elderly and frail 
patients with promising results (Bellmunt et.al., 2011). 
Sunitinib targets a number of receptor tyrosine kinases including platlet-derived growth 
factor receptors, vascular endothelial growth factor receptors, stem cell factor receptor, FMS-
like tyrosine kinase, colony stimulating receptor and neurotropic factor receptor (NCCN, 
2011). Sunitinib has established role in the treatment of metastatic RCC (Gore et.al., 2009). 
The efficacy and safety of sunitinib in elderly and poor prognosis patients was assessed in 
an expanded-access trial. Of 4371 included patients 582 (13%) had PS 2 or higher and 1418 
(32%) were aged 65 or more. Results showed a 17% objective response rate in the elderly 
and a 9% rate in PS≥2 patients. Median progression free survival was 11,3 months (95% in 
elderly and 5,1 months in poor performance group). Side effects were few and tolerable. 
Authors concluded that sunitinib is effective and safe even in groups of patients that are 
supposed to tolerate treatment less well and are usually excluded from clinical trials (Gore 
et.al., 2009, NCCN, 2011, Calvo et.al., 2010). 
Sorafenib is a small molecule that inhibits multiple tyrosine kinase receptors (NCCN, 2011). 
Treatment with sorafenib is considered to be equally effective in elderly and younger 
patients. Retrospective subgroup analysis of data from TARGET (Treatment Approach in 
Renal Cancer Global Evaluation) trial showed similar clinical benefit in patients aged 70 
years or more compared to younger ones (83,5% in older and 84,3% in younger patients) 
(Calvo et.al., 2010). Incidence of adverse events were not significantly higher in elderly 
patients receiving sorafenib. Thus sorafenib represents an important treatment option for 
elderly patients with RCC (Dutcher et.al., 2010). 
Temsirolimus was tested in a phase 3 trial comparing it to interferone therapy in patients 
with poor prognosis. Patients included in the trial had at least three of the 6 criteria for poor 
prognosis according to the modified MSCC. Patients were randomized to one of the three 
arms (temsirolimus alone, interferone alone or both treatments given together). Patients that 
received temsirolimus alone had longer overall survival compared to other two groups. (OS 
10,9 months temsirolimus alone, 7,3 interferone, 8,4 combination). The main conclusion of 
this trial is that treatment with temsirolimus alone leads to moderate prolongation of 
survival compared to treatment with interferon in patients with poor prognosis. Based on 
this trial, temsirolimus is indicated in the first line of therapy in poor prognosis patients 
(Hudes et.al., 2009,  Rejike et.al., 2010). 
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Bevacisumab is an recombinant humanized monoclonal antibody that binds and neutralizes 
circulating VEGF-A. Bevacisumab was approved by FDA for first line treatment in 
combination with IFN-ǂ (NCCN, 2011).  Concerns about administering bevacisumab in 
elderly, have been diminished by retrospective trials that showed similar efficacy and 
toxicity profiles compared with younger patients. Billemont et.al. presented data regarding 
treatment of elderly patients with all antiangiogenic therapies (sunitinib, sorafenib, 
bevacisumab). There were no toxic deaths, most common grade 3 or 4 were skin toxicity and 
mucositis. Authors conclude that antiangiogenic therapy including bevacisumab, can be 
administered safely to patients older than 75 years (Billemont et.al., 2010). Other 
retrospective trials similarly conclude that side effects, while more pronounced in the 
elderly, are well tolerated and  not dose-limiting (Calvo, 2010). 
Pazopanib is an oral VEGFR-1 and 2, PDGFR-ǂ and ǃ. It was approved for treatment of 
metastatic RCC in 2009 (NCCN, 2011). The most common side effects of pazopanib are 
diarrhoea, fatigue and hair depigmentation. The most worrying side effect is hepatotoxicity 
grade 3 present in 12% aldough fatal events are rare (0,05% of cases).  Even if only 6% of 
patients included in the trials with pazopanib were aged > 75 years, no differences in safety 
and effectiveness was observed in comparison with younger ones (Calvo et.al., 2010, FDA, 
2009, Bukowski, 2011 ).  
Everolimus is an inhibitor of mTOR. It was approved for the treatment of metastatic RCC 
after failure of sunitinib or sorafenib in 2009 based on a phase III trial named RECORD 1 
wich compared treatment with everolimus to placebo (NCCN, 2011). To assess the efficacy 
and safety of everolimus in elderly patients (>70 years), Hutson et.al. performed an 
exploratory analysis of RECORD-1 trial data. Everolimus prolonged PFS in this group of 
patients, compared to placebo. Some adverse events (eg, cough, diarrhea, asthenia, fatigue) 
were more frequent in the elderly subset vs. the overall RECORD-1 population (median age, 
61 y); but this is likely related to the intrinsic characteristics of this subpopulation, given that 
these adverse events also were more frequent in the elderly subgroup receiving placebo 
(Hutson et.al., 2010).  
According to the data obtained from trials published until now, most of the targeted 
therapies are equally effective and safe in elderly and/or frail or in young and good 
performance status patients. In most cases dose reduction is not necessary and some of the 
targeted therapies (i.e. everolimus) may even prevent worsening of renal function in 
transplant patients and those with multiple co-morbidities. The conclusion of multiple trials 
is that newer targeted drugs should be offered to elderly and/or patients with multiple co-
morbidities. It can not be stressed enough that including these patients in clinical trials is 
mandatory (Calvo et.al., 2010).  
6. Treatment with radiotherapy 
In the rare case of inoperable RCC, radiotherapy can be administered with promising 
results. In a trial of Wersall, 58 patients with inoperable or metastatic RCC received high 
dose stereotactic radiotherapy (32Gy in 4 fractions, 40Gy in 4 fractions or 45Gy in 3 
fractions). Partial response or stable disease was observed in 90% of patients and local 
control rate of 90-98% was achieved. Radiotherapy can be safely administered to elderly and 
frail patients and should be considered whenever radical therapy is not applicable (Wersall 
et.al., 2005, de Rejike et.al., 2010).  
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For patients with brain metastases, radiotherapy has an important role in their treatment. 
Using stereotactic radiotherapy similar results can be achieved as with surgical removal of 
brain metastases. The stereotactic radiotherapy is non-invasive, outpatient and can be 
applied in patients in lower PS, without worsening their condition (de Rejike et.al., 2010).  
Bone metastases represent a special problem. Patients with bone metastases are often 
symptomatic; pathological fractures, spinal cord compression and the need for surgery are 
common, and nearly 80% of untreated patients experience skeletal-related events. Until 
recently treatment options for these patients were scarce because of the chemo and ratio-
resistance of RCC. With the development of new agents like biphosphonates and targeted 
agents, better results in treatment of bone metastases regarding pain control and pathologic 
fractures can be achieved. Yuasa showed that combining radiotherapy with biphosphonates 
administration leads to higher objective response and less skeletal related events compared 
to radiation therapy alone. In administering biphosphonates caution is needed because of 
the renal impairment (Yuasa et.al., 2010). 
7. Treatment of elderly and frail metastatic RCC patients at the Institute of 
Oncology Ljubljana 
To explore the treatment approach in every-day practice we retrospectively evaluated Tany 
Nany M1 RCC patients that were treated at the Institute of Oncology Ljubljana, Slovenia, 
between 2006 and 2009 and for whom appropriate data were available. A patient was 
considered to have a metastatic disease if it was confirmed by biopsy or clear signs of 
metastatic disease were present on radiographic evaluation. Staging was performed by 
using CT imaging of thorax and abdomen. If needed other diagnostic tests were performed. 
Surgical procedures were done in hospitals other than Institute of Oncology. Performance 
status was assessed according to WHO scale. The aim was to assess possible differences in 
the treatment strategy decisions in good (WHO 0 or 1) versus poor (WHO>1) performance 
status patients.  
Medical records of 368 patients were reviewed. Patients with incomplete records were 
excluded. Patient and tumour characteristics are presented in Table 3. 
 
Variable     Metastatic RCC patients No=368 
Male 
 
Female 
268 (72,8%) 
100 (27,2%) 
Median age 63.3 (34-86) years 
Histology
 
Clear cell 
Papillary 
RCC not other specified 
Sarcomatoid 
Other rare  
 (chromophobe, collecting duct, 
mixed…) 
 
 
228 (62%) 
37 (10,0%) 
64 (17.4%) 
26 (7,1%) 
 
13 (3,5%) 
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Performance status
 
0 
1 
2 
3 
4 
Unknown 
 
 
 
89 (24,2%) 
108 (29,3%) 
57 (15,5%) 
70 (19,0%) 
38 (10,3%) 
  6 (1,6%) 
 
Co-morbidities 
 
Present 
Absent 
Unknown 
 
 
93 (25,3%) 
262 (71,2%) 
13 (3,5%) 
Table 3. Patient and tumour caracteristics 
All patients were reviewed by the multidisciplinary board that consists of an urologist, a 
medical oncologist and a radiation oncologist. All patients had proven metastatic disease 
before presentation to the board. Administered treatment is shown in Table 4. 
 
Treatment mode Number of patients treated 
(percentage)  
Surgery 
 
Nephrectomy with radical intent 
(performed before metastatic disease 
was present) 
 
Cytoreductive nephrectomy 
 
Tumour embolisation 
 
 
162 (44,1%) 
 
 
106 (28,8%) 
 
  43 (11,6%) 
Systemic therapy
 
Immunotherapy 
 
Targeted therapy 
 
 
 
50 (13,6%) 
 
156 (42,4%) 
Watchful waiting 
Best supportive care 
12 (3,3%) 
150 (40,0%) 
Table 4. Treatment options 
To establish possible differences in the decision of treatment strategy in different groups of 
patients, a comparison was made. All treatment decisions were made by a multidisciplinary 
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team of oncologists on the basis of medical documentation and clinical examination of the 
patient by a member of the team. Comparison between groups was done with X2 test. 
Differences between patients in good vs. poor performance status, patients with or without 
major co-morbidities and younger vs. elderly patients is shown in Table 5. 
 
 Systemic therapy 
(immunotherapy or 
targeted therapy) 
Best supportive care or 
observation 
Performance status
 
PS 0,1 
 
 
PS>1 
 
179 (90,8%) 
 
 
26 (15,7%) 
 
18 (9,2%) 
 
139 (84,3%) 
                                    p<0,01 
Co-morbidities
 
Not present 
 
Present 
 
 
160 (61%) 
 
50 (53,7%) 
 
 
102 (39%) 
 
43 (46,3%) 
 
                                    p=0,76 
Age 
 
< 75 years 
 
≥ 75 years 
 
 
 
151 (72,7%) 
 
12 (7,5%) 
 
 
57 (27,3%) 
 
148 (92,5)% 
 
                                    p<0,01 
Table 5. Differences in treatment decisions  
As expected, the patient’s performance status has an important impact on treatment 
decision. Patients in good PS receive systemic therapy in much greater percentage of cases 
than patients in poor PS. Patients in poor PS are more likely to tolerate less well systemic 
therapy and treatment decisions in every-day practice reflects the knowledge of this fact. 
Defining PS, even if it is a subjective measure, is very important and should be made by an 
experienced clinician. Still, some patients in good PS do not get the systemic therapy and 
some in poor PS get it. This reflects the influence of other factors, like age of the patients and 
co-morbidities on treatment decisions.  
The difference between treatment decisions based on co-morbidities is not clear. In our 
review, systemic treatment was administered to many patients with co-morbidities. An 
explanation for this is, that according to known data, most of the available targeted 
therapies are effective and safe for the majority of patients with co-morbidities. 
Nevertheless, half of the patients with co-morbidities present do not get the specific therapy. 
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With evolving results from clinical trials, new data on safety and efficacy will become 
available which will help clinicians in treatment decisions.  
Age has a huge impact on treatment decisions. Less than 10% of metastatic RCC patients 
older than 75 years get systemic therapy prescribed. Prescribing targeted therapies to 
elderly patients still represents a challenge to clinicians. This is in accordance with the 
widely established tendency to believe that older patients tolerate the treatment less well 
and develop adverse events in higher percentage and at greater degree. Recent evidence 
shows that available treatments (targeted therapy) are safe and efficient in elderly as well as 
young patients (Calvo et.al., 2010).  
8. Conclusions 
Longer life expectancy together with the growing incidence of RCC has raised the number 
of elderly and frail patients with this malignancy. Tailoring treatment to the individual 
patient according to the tumour stage and patient general condition is the primary goal of 
treatment. Treatment options for the elderly and frail are multiple and vary in their 
aggressiveness. Finding the right treatment for the right patient can be a difficult task for 
oncologists. Improvement in all fields from surgery to targeted therapies led to broader 
treatment choice. The problem that remains is that often no evidence exists which treatment 
combination to use, since much too often these patients are excluded form clinical trials. 
How to encourage investigators to design clinical trials so as that these patients can be 
included in greater numbers, remains a difficult open question especially in large trials 
testing new drugs. Conducting trials addressing these populations after the drug has been 
approved for use in good prognosis-good performance patients deprives others of a new 
drug which is often well tolerable and effective. 
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